Trials
1 active
12 in total
Targets
—
None known yet
What this is
- How it works
- A cell therapy: living cells given to the patient as the treatment.-cel: cell therapies WHO name stem
- How it’s given
- “Remestemcel-L is comprised of ex-vivo cultured adult human MSC”In the company’s words, NCT07568535 on ClinicalTrials.gov
- Tested for
- GVHD - Graft-Versus-Host Disease
- Main trialPhase 3
- “This study is a randomized, double-blind, placebo-controlled, multicenter Phase III trial to compare the efficacy and safety of remestemcel-L-rknd (remestemcel-L), ex-vivo cultured adult human mesenchymal stromal cells (MSC), combined with ruxolitinib vs. ruxolitinib combined with placebo as second-line therapy in adult patients with Grade III-IV steroid-refractory acute graft-versus-host disease (SR-aGVHD).”In the company’s words, NCT07568535 on ClinicalTrials.gov
- Other names
- Prochymal · Adult Human Mesenchymal Stem Cells · hMSCs · Mesenchymal Stem Cells
Other drugs for GVHD - Graft-Versus-Host Disease
- IbrutinibJohnson & Johnson (Janssen) · Phase 3
- AxatilimabIncyte · Syndax Pharmaceuticals · Phase 3
- DFL24498Dompé Farmaceutici S.p.A · Phase 3
- RovadicitinibChia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase 3
- RhPRG4Lubris Bio Pty Ltd · Phase 2
- Orca-TOrca Biosystems, Inc. · Phase 2
Coming up1
- 28 Feb 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials12
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 28 Feb 2028 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Added to Ruxolitinib for Grade III-IV Steroid-Refractory Acute Graft-Versus-Host Disease | |
| Phase 3Completed | 26 Dec 2008 | Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD) | |
| Phase 3Completed | 14 Jul 2009 | Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD) | |
| Phase 3Completed | 15 Sep 2014 | Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease | |
| Phase 3Completed | 15 Sep 2014 | Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease | |
| Phase 3Completed | 9 Apr 2018 | A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD) | |
| Phase 3Completed | 15 Jun 2018 | Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD | |
| Phase 2Completed | 25 Apr 2006 | Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD Participants | |
| Phase 2Completed | 28 Jul 2006 | Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD) | |
| Phase 2Completed | 9 Mar 2009 | PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | |
| Phase 2Completed | 12 Dec 2010 | PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM) | |
| Phase 2Completed | 18 May 2011 | Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026